STRENGTHS AND LIMITATIONS OF THIS STUDY
acne
ACNE
Our study is based on individual patient-level data collected alongside the first large pragmatic, parallel, double-blind, randomised trial of spironolactone for acne.In addition to the base-case analysis seeking to answer the question of whether spironolactone is cost-effective compared with no active systemic treatment (both groups could use routine topical treatments) in women with persistent acne, a number of sensitivity analyses were undertaken to provide a range on estimates of cost-effectiveness under different scenarios.Differential rates of missing data between groups over time were addressed by undertaking both a complete case analysis and multiple imputation to explore the impact of missing data on the study conclusions.As the study was constrained by the design of the clinical trial, the base-case did not reflect real-world prescribing in the comparator group, limiting interpretation of the results.The results reflect the method of data collection and may have been limited as a consequence of resource-use under-reporting, short time-frame and limited sensitivity of the EQ-5D outcome measure in patients with acne.